Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CCW702 |
Synonyms | |
Therapy Description |
CCW702 is a bispecific antibody that binds PSMA and CD3, potentially resulting in increased cytotoxic T-cell response against PSMA-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CCW702 | CCW-702|CCW 702 | CD3 Antibody 99 PSMA Antibody 20 | CCW702 is a bispecific antibody that binds PSMA and CD3, potentially resulting in increased cytotoxic T-cell response against PSMA-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04077021 | Phase I | CCW702 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |